Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Innate Pharma SA - Third quarter 2017 report

share with twitter share with LinkedIn share with facebook
share via e-mail
11/20/2017 | 02:18pm CET

Innate Pharma SA (the 'Company' - Euronext Paris: FR0010331421 - IPH) today announces its revenues and cash position for the first nine months of 2017.

Mondher Mahjoubi, Chief Executive Officer of Innate Pharma, commented: 'Our robust cash position as of September 30 2017, provides us with the ability to further invest in our proprietary discovery and development portfolio of first-in-class immuno-oncology programs, including our lead product candidates IPH4102 and IPH5401. Clinical development plans for both candidates are in the process of being shaped and we expect to provide an update early in 2018. Following the promising results for IPH4102 presented at the 2017 EORTC meeting, Innate Pharma remains committed to bringing IPH4102 to patients on our own as quickly as possible, in line with our strategy of becoming an independent, fully integrated biopharmaceutical company.'

Cash, cash equivalents and financial assets of the Company amounted to EUR195.7 million at September 30, 2017, including current and non-current financial assets (EUR239.6 million at September 30, 2016). At the same date, its financial liabilities amounted to EUR4.9 million (EUR5.6 million at September 30, 2016).

The net consumption of cash, cash equivalents and financial assets amounted to EUR8.4 million for the third quarter of 2017. This includes the collection during the period of the research tax credit relating to the year 2016 (EUR8.8 million).

For the nine-month period ended September 30, 2017, revenue results from the co-development and commercialization agreement with AstraZeneca, corresponding to the recognition over the period of the initial payment received in April 2015 (EUR27.2 million for the same period in 2016).

The nine-month period ended September 30, 2016 included a EUR0.7 million amount resulting from the collaboration and licensing agreement with Bristol-Myers Squibb corresponding to the recognition of the upfront payment received in July 2011.

Regarding the co-development and commercialization agreement with AstraZeneca, the Company recognizes the initial payment of $250 million over the period during which the Company is committed to complete the studies and based on actual expenses incurred. The measurement of progress has been based on actual expenses incurred compared to the total estimated amount of expenses to be incurred for these studies.

About Innate Pharma: Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity. Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The Company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company. Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.

Disclaimer: This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.


Dr Markus Metzger

Tel: +33 (0)4 30 30 30 30

Email: [email protected]

(C) 2017 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
11/20 Innate Pharma SA - Third quarter 2017 report
11/17 LABORATORY OF AMERICA : LabCorp Announces New Expanded Use for PD-L1 Test with B..
11/16 BRISTOL MYERS SQUIBB : Opdivo Plus Yervoy Combination Delivered Overall Survival..
11/16 BRISTOL MYERS SQUIBB : Trademark Application for "ACCESS VIROLOGY" Filed
11/16 BRISTOL MYERS SQUIBB : Opdivo nivolumab Demonstrates Superior Three-Year Surviva..
11/16 BRISTOL MYERS SQUIBB : to Highlight Clinical and Translational Research at the S..
11/16 BRISTOL MYERS SQUIBB : An Application for the Trademark "AVGLAZI" Has Been Filed..
11/16 BRISTOL MYERS SQUIBB : to Take Part in Jefferies London Healthcare Conference
11/16 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Yield New Information a..
11/16 BRISTOL MYERS SQUIBB : and Five Prime Present Phase 1a/1b Data Evaluating Cabira..
More news
News from SeekingAlpha
08:33a YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/20 Roche Rocks On With More Good News
11/20 Pfizer Scores Sutent Win, But Bristol-Myers Looks To Steal Its Thunder
11/17 EXELIXIS : Primed For Excellence
11/17 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 58 Increases Expected By The End Of Janua..
Financials ($)
Sales 2017 20 634 M
EBIT 2017 5 598 M
Net income 2017 4 351 M
Debt 2017 295 M
Yield 2017 2,60%
P/E ratio 2017 23,35
P/E ratio 2018 20,37
EV / Sales 2017 4,84x
EV / Sales 2018 4,61x
Capitalization 99 511 M
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 63,1 $
Spread / Average Target 3,8%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550